

# ClariFind™ Product Comparison

ClariFind offers several advantages compared to other tests on the market. Find out how ClariFind stands out among the rest in the highlighted sections below.

	ClariFind Baylor Genetics	PCDx Paradigm	FoundationOne Foundation	Comprehensive Genomic Profiling PLUS (CGP+) Caris Molecular Intelligence
Turnaround Time (TAT)	14 days	4 - 5 business days	14 day average	8 - 14 days
Hematologic Malignancies and Solid Tumor offered together	Together	Heme not available	Separate	Separate
Biomarkers Tested by NGS	277	134	315 cancer-related genes, and select introns from 28 genes that are often rearranged or altered in cancer	614
Immunotherapy Biomarkers	TMB (score only), MSI by PCR offered separately	PD-L1 and MMR by IHC	TMB & MSI	TMB, MSI, PD-L1 and MMR by IHC
Protein Expression Tested by IHC	PD-L1 by IHC offered separately	24 IHC markers	PD-L1 by IHC offered separately	21 IHC markers
Average Depth of Coverage	1,500x (UMI non-duplicates)	>5,000x	>500x	>750x
NGS Chemistry	Amplicon-based unique molecular identifiers (UMI) - more accurate and sensitive low-level variant detection	Amplicon-based	Capture-based	Capture-based
Sample requirement	>=20% tumor recommended (but lower not rejected); 40 ng DNA input; low failure rate due to amplicon-based chemistry	>=4% tumor; low failure rate due to amplicon-based chemistry	>=20% tumor; sample requirement presumably higher due to capture-based chemistry, thus higher failure rate with limited samples	>=20% tumor; sample requirement presumably higher due to capture-based chemistry, thus higher failure rate with limited samples
Limit of detection for base substitutions	Report as low as 1% (2% at >97% sensitivity, >=5% at >99.9% sensitivity)	Not published, presumably low due to high average coverage	5-10% at 99% sensitivity	>=5% at 99% sensitivity
Alterations Tested by NGS	---	---	---	---
mRNA Expression	No	Yes	No	No
DNA Mutations	Yes	Yes	Yes	Yes
Copy Number Alterations (CNA)	Yes	Yes	Yes	Yes
Fusions/Rearrangements	FISH offered separately	Yes	Yes	Yes
Therapy and Clinical Trial Matching	Yes	Yes	Yes	Yes
Interpretative summary written by board-certified lab directors	Yes	No	No	No
Report follows recent AMP variant classification guidelines	Yes	No	No	No
Report highlights nearby clinical trials (within 100 mile radius)	Yes	No	No	No
Academic vs. Commercial	Academic/Commercial hybrid	Commercial	Commercial - owned by Roche	Commercial
Lab offers other comprehensive genetic testing (cytogenetics, FISH, hereditary cancer, constitutional, etc.)	Yes	No	No	No
Source	<a href="http://www.baylorgenetics.com/clarifind/">www.baylorgenetics.com/clarifind/</a>	<a href="http://www.paradigmdx.com/pcdx/physician-faq/">www.paradigmdx.com/pcdx/physician-faq/</a>	<a href="http://www.foundationmedicine.com/genomic-testing/foundation-one/">www.foundationmedicine.com/genomic-testing/foundation-one/</a>	<a href="http://www.carismoleculairintelligence.com/profiling-menu/mi-profile-usa-excluding-new-york/">www.carismoleculairintelligence.com/profiling-menu/mi-profile-usa-excluding-new-york/</a>

**DISCLAIMER:** Information accessed July 1, 2018. Product Comparison is provided by Baylor Genetics, and reasonable efforts have been made to ensure the accuracy of this content to the best of our knowledge. However, Baylor Genetics does not guarantee the accuracy or completeness of this content and is not responsible for information provided from other companies' websites, including product updates or additional product information beyond what is listed above, or for product information that is not made readily accessible to the general public. Please check the respective company websites and product literature for more information on each testing product. The patient's physician is encouraged to research and be knowledgeable of all pertinent testing options available at the time of test ordering.